# Immuneel Therapeutics

Source: https://onco.cc/companies/immuneel/  
OnCo record `immuneel` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Bengaluru cell therapy company that brought Barcelona's academic CD19 CAR-T to India as Qartemi, the country's second approved CAR-T, after the IMAGINE trial.

## Summary

Immuneel Therapeutics is a private cell and gene therapy company based at Narayana Health City in Bengaluru, formed to make CAR-T therapy affordable and accessible in India. Its lead product, varnimcabtagene autoleucel (IMN-003A, brand Qartemi), is the Indian version of ARI-0001, the academic CD19 CAR-T developed at Hospital Clinic de Barcelona and approved in Spain under the hospital exemption. Immuneel ran IMAGINE, the first industry-sponsored CAR-T trial in India, a phase 2 study in relapsed or refractory B-cell malignancies reported at ASH 2023 and in Hematological Oncology, and Qartemi received CDSCO market authorisation for relapsed or refractory B-cell lymphoma in 2024. The company won Endpoints' most promising biopharma start-up and APAC cell and gene therapy start-up awards in 2023.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Bengaluru
- Type: cell-therapy
- Website: https://www.immuneel.com

## Sources

- Official website: https://www.immuneel.com
- IMAGINE study (ASH 2023 abstract): https://doi.org/10.1182/blood-2023-181585

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Point-of-care and decentralised cell manufacturing](https://onco.cc/technologies/point-of-care-cell-manufacturing/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- drugs: [Varnimcabtagene autoleucel](https://onco.cc/drugs/varnimcabtagene-autoleucel/)
- institutions: [Narayana Health (Mazumdar Shaw Medical Centre)](https://onco.cc/institutions/narayana-health/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/)
- trials: [IMAGINE (varnimcabtagene autoleucel, Immuneel)](https://onco.cc/trials/imagine-varnimcabtagene/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/immuneel.json